Founders Capital Management (Texas)’s Sangamo Therapeutics SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.58K | Hold |
14,000
| – | – | ﹤0.01% | 293 |
|
|
2025
Q1 | $9.18K | Hold |
14,000
| – | – | 0.01% | 279 |
|
|
2024
Q4 | $14.3K | Sell |
14,000
-2,000
| -13% | -$2.04K | 0.01% | 256 |
|
|
2024
Q3 | $13.9K | Buy |
16,000
+6,000
| +60% | +$5.2K | 0.01% | 266 |
|
|
2024
Q2 | $3.58K | Hold |
10,000
| – | – | ﹤0.01% | 321 |
|
|
2024
Q1 | $6.7K | Buy |
10,000
+8,000
| +400% | +$5.36K | ﹤0.01% | 304 |
|
|
2023
Q4 | $1.09K | Sell |
2,000
-2,000
| -50% | -$1.09K | ﹤0.01% | 361 |
|
|
2023
Q3 | $2.4K | Hold |
4,000
| – | – | ﹤0.01% | 367 |
|
|
2023
Q2 | $5.2K | Hold |
4,000
| – | – | ﹤0.01% | 341 |
|
|
2023
Q1 | $7K | Buy |
4,000
+2,000
| +100% | +$3.5K | 0.01% | 340 |
|
|
2022
Q4 | $6K | Buy |
2,000
+1,000
| +100% | +$3K | ﹤0.01% | 333 |
|
|
2022
Q3 | $5K | Hold |
1,000
| – | – | ﹤0.01% | 344 |
|
|
2022
Q2 | $4K | Hold |
1,000
| – | – | ﹤0.01% | 373 |
|
|
2022
Q1 | $8K | Hold |
1,000
| – | – | 0.01% | 281 |
|
|
2021
Q4 | $8K | Hold |
1,000
| – | – | 0.01% | 281 |
|
|
2021
Q3 | $9K | Buy |
+1,000
| New | +$9K | 0.01% | 279 |
|